Article Text
Test yourself
A tough one to swallow
Statistics from Altmetric.com
Footnotes
Contributors EM: was responsible for project concept and design, acquisition of data, manuscript preparation, and critical revision of manuscript for intellectual content. JC, NC, JP and NEA: critically revised the manuscript for intellectual content and was involved in supervision of the project.
Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent Obtained.
Provenance and peer review Not commissioned; externally peer reviewed. This paper was reviewed by Jon Walters, Swansea, UK.
Read the full text or download the PDF:
Other content recommended for you
- Autoantibody testing in idiopathic inflammatory myopathies
- Evaluation and treatment of inflammatory myopathies
- SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies
- Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort
- Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups
- Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies
- The EuroMyositis registry: an international collaborative tool to facilitate myositis research
- Hyperacute muscle weakness in an unusual coexistence of antisignal recognition particle and anti-Mi-2 antibodies
- Proximal myopathy: diagnostic approach and initial management
- Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy